OraPharma
Stage
Acquired | AcquiredTotal Raised
$33.9MValuation
$0000About OraPharma
OraPharma is a specialty pharmaceutical company that develops and commercializes products that improve and maintain oral health. The company is dedicated to delivering scientifically and technologically advanced products to dental professionals and their practices. OraPharma's lead product, ARESTIN (minocycline hydrochloride), is a locally administered antibiotic for the treatment of periodontitis that utilizes an advanced controlled-release delivery system. In February 2003, OraPharma was acquired by Johnson & Johnson for $104 million. In January 2011, Water Street Healthcare Partners acquired OraPharma from Johnson & Johnson. In June 2012, Water Street exited its investment and sold OraPharma to Valeant Pharmaceuticals. The valuation of OraPharma was $312 million. Other terms of the deal were not released.
Missing: OraPharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: OraPharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing OraPharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
OraPharma is included in 1 Expert Collection, including Dental Health.
Dental Health
959 items
Companies delivering dental care products and services. Excludes practice networks.
OraPharma Patents
OraPharma has filed 7 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/26/2013 | 2/14/2017 | Oral hygiene, Conditions of the mucous membranes, Oral mucosal pathology, Periodontology, Salivary gland pathology | Grant |
Application Date | 8/26/2013 |
|---|---|
Grant Date | 2/14/2017 |
Title | |
Related Topics | Oral hygiene, Conditions of the mucous membranes, Oral mucosal pathology, Periodontology, Salivary gland pathology |
Status | Grant |
Latest OraPharma News
Oct 25, 2022
Jess Giebel, professional education manager at OraPharma and a dental hygienist, spoke with Becker's on Oct. 24 to discuss the best way dentists can support hygienists. Editor's note: Response has been lightly edited for length and clarity. Question: What do dental hygienists need in 2023 to be successful? Jess Giebel: There is a certain amount of support that an office and a team can show and also with the different dental companies that are out there. So with OraPharma we're really focusing on how we can support hygienists and how we can support the dental team. [Things like] being able to offer education and different websites that maybe they can direct their patients to, just making sure that there's available resources on that end. We actually have a back-to-basics website that is amazing that will help with patients' understanding of the disease state, as well as little tidbits and nuggets of information for the hygienist. We're always learning and growing, especially hygienists, with continuing education and things like that. Professionally and personally, being able to be available at conferences — which are a huge support because that's your peer-to-peer relationship. Maybe the team can go to different conferences and get teamwork together and support the hygienists that way, too.
OraPharma Frequently Asked Questions (FAQ)
Where is OraPharma's headquarters?
OraPharma's headquarters is located at 5 Walnut Grove Drive, Horsham.
What is OraPharma's latest funding round?
OraPharma's latest funding round is Acquired.
How much did OraPharma raise?
OraPharma raised a total of $33.9M.
Who are the investors of OraPharma?
Investors of OraPharma include Bausch Health, Water Street Healthcare Partners, Johnson & Johnson, Canaan Partners, Biotechnology Investments and 8 more.
Who are OraPharma's competitors?
Competitors of OraPharma include La Jolla Pharmaceutical Company, Elcelyx Therapeutics, Kamada Pharmaceuticals, arGentis Pharmaceuticals, Athersys and 13 more.
Compare OraPharma to Competitors
Savient Pharmaceuticals is a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical products that target unmet medical needs in rheumatology and other specialty niche medical markets. The company's focus is on the company's biologic product candidate, Puricase (pegloticase) that has been developed for treatment-failure gout (TFG).
arGentis Pharmaceuticals is a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept for chronic diseases.
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.
HealOr is a biopharmaceutical company committed to the development and commercialization of therapeutics impacting skin cells' properties for the purpose of treating various skin pathologies. HealOr has completed a safety and primary efficacy study of its lead drug HO/03/03 a topical drug for the treatment of diabetic foot ulcers and venous leg ulcers.
Affibody is a private clinical-stage biotech company. It specializes in the discovery of antibody mimetics that provide biodistribution flexibility, tissue penetration, and tumor targeting. The company was founded in 1998 and is based in Solna, Sweden.
VidaGene,Inc., is a biopharmaceutical company that aims to develop pharmaceuticals based on modulation of the vitamin D receptor (VDR). VidaGene seeks to develop entirely new VDR modulators for large pharmaceutical markets such as cancer-related thrombosis, osteoporosis and psoriasis.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.